Unknown PHASE2 INTERVENTIONAL 2-arm NCT05559450

Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL

A Multicenter ,Prospective, Randomized Clinical Trial of Blinatumomab As a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in High Risk Precursor B-cell Acute Lymphoblastic Leukemia

Sponsor: First Affiliated Hospital of Wannan Medical College

Conditions B-cell Acute Lymphoblastic Leukemia

Interventions Blinatumomab Conventional therapy

Updated 4 times since 2022 Last updated: Sep 26, 2022 Started: Feb 1, 2022 Primary completion: Jan 1, 2024 Completion: Jan 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates B-cell Acute Lymphoblastic Leukemia and is currently ongoing. First Affiliated Hospital of Wannan Medical College leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Oct 2022 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Wannan Medical College
Fujian Medical University Union Hospital
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The First Affiliated Hospital of Soochow University
The First People's Hospital of Changzhou
Wuxi People's Hospital
Zhongda Hospital

Data source: The First Affiliated Hospital of Soochow University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suzhou, China